Hoth Therapeutics Relocates Executive Offices
Ticker: HOTH · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1711786
| Field | Detail |
|---|---|
| Company | Hoth Therapeutics, Inc. (HOTH) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, administrative
Related Tickers: HOTH
TL;DR
HOTH moved its HQ to NYC, effective 6/14.
AI Summary
Hoth Therapeutics, Inc. filed an 8-K on June 17, 2024, reporting a change in its principal executive offices to 590 Madison Avenue, 21st Floor, New York, NY 10022, effective June 14, 2024. The company also updated its telephone number to (646) 756-2997.
Why It Matters
A change in principal executive offices can indicate operational shifts or strategic realignments for the company.
Risk Assessment
Risk Level: low — This filing primarily concerns administrative changes related to the company's office location and contact information, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Hoth Therapeutics, Inc. (company) — Registrant
- 590 Madison Avenue, 21st Floor, New York, NY 10022 (location) — New Principal Executive Offices
- (646) 756-2997 (phone_number) — New Business Phone Number
- June 14, 2024 (date) — Effective date of office change
- June 17, 2024 (date) — Filing date
FAQ
What is the new address for Hoth Therapeutics' principal executive offices?
The new address for Hoth Therapeutics' principal executive offices is 590 Madison Avenue, 21st Floor, New York, NY 10022.
When was the change in principal executive offices effective?
The change in principal executive offices was effective as of June 14, 2024.
What is the new telephone number for Hoth Therapeutics?
The new telephone number for Hoth Therapeutics is (646) 756-2997.
What type of filing is this for Hoth Therapeutics?
This is a Current Report on Form 8-K.
In which state is Hoth Therapeutics incorporated?
Hoth Therapeutics, Inc. is incorporated in Nevada.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-06-17 16:41:10
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value HOTH The Nasdaq Stock Mar
Filing Documents
- ea0207966-8k_hoththera.htm (8-K) — 25KB
- ea020796601ex3-1_hoththera.htm (EX-3.1) — 6KB
- 0001213900-24-053359.txt ( ) — 206KB
- hoth-20240614.xsd (EX-101.SCH) — 3KB
- hoth-20240614_lab.xml (EX-101.LAB) — 33KB
- hoth-20240614_pre.xml (EX-101.PRE) — 22KB
- ea0207966-8k_hoththera_htm.xml (XML) — 4KB
03 Amendments to Articles of Incorporation
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On June 14, 2024, the board of directors (the "Board") of Hoth Therapeutics, Inc. (the "Company") approved an amendment (the "Amendment") to the Company's Amended and Restated Bylaws, as amended (the "Bylaws"). The Amendment amends and restates in its entirety Article II, Section 2.7(b) of the Bylaws to clarify the shareholders entitled to vote on proposals at a meeting of the Company's shareholders. The foregoing description of the Amendment set forth herein does not purport to be complete and is qualified in its entirety by the full text of the Amendment which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Amendment No. 2 to the Amended and Restated Bylaws of Hoth Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 17, 2024 Hoth Therapeutics, Inc. /s/ Robb Knie Robb Knie Chief Executive Officer 2